Catalent, Inc. (CTLT)
USD 63.48
(0.0%)
USD 63.48
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 4.98 Billion USD | 1.42% |
| 2023 | 4.84 Billion USD | 15.4% |
| 2022 | 4.2 Billion USD | 29.65% |
| 2021 | 3.24 Billion USD | 7.39% |
| 2020 | 3.01 Billion USD | 1.98% |
| 2019 | 2.95 Billion USD | 8.75% |
| 2018 | 2.72 Billion USD | 30.85% |
| 2017 | 2.07 Billion USD | 11.78% |
| 2016 | 1.86 Billion USD | -1.45% |
| 2015 | 1.88 Billion USD | -30.35% |
| 2014 | 2.71 Billion USD | 0.71% |
| 2013 | 2.69 Billion USD | 0.3% |
| 2012 | 2.68 Billion USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 4.94 Billion USD | 2.0% |
| 2024 Q2 | 5.01 Billion USD | 1.37% |
| 2024 FY | 4.98 Billion USD | 2.87% |
| 2024 Q4 | 4.98 Billion USD | -0.04% |
| 2024 Q3 | 4.99 Billion USD | -0.48% |
| 2023 FY | 4.84 Billion USD | 15.4% |
| 2023 Q3 | 4.84 Billion USD | -0.33% |
| 2023 Q4 | 4.84 Billion USD | 0.0% |
| 2023 Q2 | 4.86 Billion USD | 15.37% |
| 2023 Q1 | 4.21 Billion USD | 0.02% |
| 2022 Q2 | 4.23 Billion USD | -1.95% |
| 2022 Q3 | 4.2 Billion USD | -0.8% |
| 2022 FY | 4.2 Billion USD | 29.65% |
| 2022 Q1 | 4.31 Billion USD | 33.23% |
| 2022 Q4 | 4.21 Billion USD | 0.38% |
| 2021 Q3 | 3.23 Billion USD | 5.95% |
| 2021 FY | 3.24 Billion USD | 7.39% |
| 2021 Q1 | 3.05 Billion USD | 1.35% |
| 2021 Q2 | 3.05 Billion USD | -0.09% |
| 2021 Q4 | 3.24 Billion USD | 0.1% |
| 2020 Q3 | 3.19 Billion USD | 10.41% |
| 2020 Q1 | 2.93 Billion USD | -0.89% |
| 2020 Q2 | 2.89 Billion USD | -1.23% |
| 2020 Q4 | 3.01 Billion USD | -5.65% |
| 2020 FY | 3.01 Billion USD | 1.98% |
| 2019 Q1 | 2.27 Billion USD | -16.25% |
| 2019 FY | 2.95 Billion USD | 8.75% |
| 2019 Q4 | 2.95 Billion USD | 35.34% |
| 2019 Q3 | 2.18 Billion USD | -0.6% |
| 2019 Q2 | 2.19 Billion USD | -3.48% |
| 2018 Q3 | 2.77 Billion USD | 1.27% |
| 2018 Q4 | 2.72 Billion USD | -2.01% |
| 2018 FY | 2.72 Billion USD | 30.85% |
| 2018 Q1 | 2.1 Billion USD | 1.3% |
| 2018 Q2 | 2.74 Billion USD | 30.17% |
| 2017 Q1 | 1.93 Billion USD | 4.13% |
| 2017 FY | 2.07 Billion USD | 11.78% |
| 2017 Q3 | 2.04 Billion USD | 1.22% |
| 2017 Q4 | 2.07 Billion USD | 1.5% |
| 2017 Q2 | 2.02 Billion USD | 4.5% |
| 2016 FY | 1.86 Billion USD | -1.45% |
| 2016 Q4 | 1.86 Billion USD | -0.55% |
| 2016 Q3 | 1.87 Billion USD | -0.1% |
| 2016 Q2 | 1.87 Billion USD | -0.59% |
| 2016 Q1 | 1.88 Billion USD | -0.21% |
| 2015 Q2 | 1.93 Billion USD | 6.47% |
| 2015 Q1 | 1.81 Billion USD | -32.98% |
| 2015 FY | 1.88 Billion USD | -30.35% |
| 2015 Q4 | 1.88 Billion USD | 0.32% |
| 2015 Q3 | 1.88 Billion USD | -2.71% |
| 2014 Q2 | 2.73 Billion USD | 1.0% |
| 2014 Q1 | 2.7 Billion USD | 0.45% |
| 2014 FY | 2.71 Billion USD | 0.71% |
| 2014 Q4 | 2.71 Billion USD | 0.35% |
| 2014 Q3 | 2.7 Billion USD | -1.08% |
| 2013 Q4 | 2.69 Billion USD | 0.0% |
| 2013 FY | 2.69 Billion USD | 0.3% |
| 2013 Q1 | - USD | 0.0% |
| 2012 FY | 2.68 Billion USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Amneal Pharmaceuticals, Inc. | 2.75 Billion USD | -81.347% |
| Bausch Health Companies Inc. | 22.38 Billion USD | 77.72% |
| Emergent BioSolutions Inc. | 877.5 Million USD | -468.433% |
| Elanco Animal Health Incorporated | 5.77 Billion USD | 13.613% |
| Perrigo Company plc | 4.07 Billion USD | -22.453% |
| Teva Pharmaceutical Industries Limited | 20.15 Billion USD | 75.249% |
| Zoetis Inc. | 6.8 Billion USD | 26.679% |